Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application

Santhera Pharmaceuticals has stopped a phase 3 trial of Duchenne muscular dystrophy (DMD) drug idebenone after it failed an interim analysis. The setback prompted Santhera to outline plans to pull a filing for approval and restructure around a second asset that it secured global rights to last month.